Intervacc
Intervacc is a Swedish biotechnology company dedicated to developing new vaccines based on recombinant fusion proteins to meet the growing demand for effective animal health solutions. With a focus on innovative technology platforms and a strong research background from Karolinska Institutet and Sveriges Lantbruksuniversitet, Intervacc aims to lead in the global animal vaccine market. The company collaborates with subsidiaries Nordvacc Läkemedel and Mybac-Vettech Laboratory to enhance animal health and welfare, offering vaccines such as Strangvac for equine strangles and other candidates targeting bacterial infections in animals. Intervacc emphasizes the importance of vaccines in reducing antibiotic use and combating antibiotic resistance.
Industries
Nr. of Employees
small (1-50)
Intervacc
Products
Recombinant multi-component vaccine for equine strangles (marketed)
A recombinant multi-component subunit vaccine against Streptococcus equi (equine strangles) that has undergone clinical evaluation and received marketing authorization in several jurisdictions.
Vaccine candidate against Streptococcus suis (porcine) — preclinical
A recombinant subunit vaccine candidate targeting Streptococcus suis infections in pigs, currently at preclinical development stage.
Vaccine candidate against Staphylococcus aureus mastitis (bovine) — preclinical
A recombinant subunit vaccine candidate aimed at preventing Staphylococcus aureus–associated mastitis in dairy cattle, currently in preclinical development.
Recombinant fusion-protein vaccine technology platform
Platform approach for combining key bacterial surface protein domains into fused recombinant proteins to produce multi-component subunit vaccines with reduced reactogenicity and potential DIVA capability.
Recombinant multi-component vaccine for equine strangles (marketed)
A recombinant multi-component subunit vaccine against Streptococcus equi (equine strangles) that has undergone clinical evaluation and received marketing authorization in several jurisdictions.
Vaccine candidate against Streptococcus suis (porcine) — preclinical
A recombinant subunit vaccine candidate targeting Streptococcus suis infections in pigs, currently at preclinical development stage.
Vaccine candidate against Staphylococcus aureus mastitis (bovine) — preclinical
A recombinant subunit vaccine candidate aimed at preventing Staphylococcus aureus–associated mastitis in dairy cattle, currently in preclinical development.
Recombinant fusion-protein vaccine technology platform
Platform approach for combining key bacterial surface protein domains into fused recombinant proteins to produce multi-component subunit vaccines with reduced reactogenicity and potential DIVA capability.
Services
Distribution and sales of veterinary vaccines and medicines
Commercial distribution, marketing and sales operations for veterinary vaccines and pharmaceuticals in Nordic and selected European markets through an established sales organization.
Accredited veterinary microbiology and mycology laboratory testing
Laboratory testing services offering accredited bacteriology and mycology analyses for clinical veterinary diagnostics.
Distribution and sales of veterinary vaccines and medicines
Commercial distribution, marketing and sales operations for veterinary vaccines and pharmaceuticals in Nordic and selected European markets through an established sales organization.
Accredited veterinary microbiology and mycology laboratory testing
Laboratory testing services offering accredited bacteriology and mycology analyses for clinical veterinary diagnostics.
Expertise Areas
- Veterinary vaccine development
- Recombinant protein subunit vaccine platforms
- Animal clinical trial execution and evaluation
- GMP biomanufacturing of recombinant proteins
Key Technologies
- Recombinant fusion-protein vaccine design
- Subunit vaccine platforms
- E. coli recombinant protein expression
- GMP biomanufacturing